Dr Otto Frederick Dickman Iv, MD | |
90 West Main, Emery Medical Center, Castle Dale, UT 84513-0607 | |
(435) 381-2305 | |
(435) 381-4535 |
Full Name | Dr Otto Frederick Dickman Iv |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | 90 West Main, Castle Dale, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1619065943 | NPI | - | NPPES |
621762357076 | Medicaid | UT | |
621762357080 | Medicaid | UT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 495-6304-1205 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Otto Frederick Dickman Iv, MD Po Box 607, Emery Medical Center, Castle Dale, UT 84513-0607 Ph: (435) 381-2305 | Dr Otto Frederick Dickman Iv, MD 90 West Main, Emery Medical Center, Castle Dale, UT 84513-0607 Ph: (435) 381-2305 |
News Archive
The Huffington Post breaks down the good and bad news surrounding what people may pay next year for coverage in the wake of the health law. Meanwhile, Modern Healthcare takes a look at how the Obama administration decision to let people keep health coverage that didn't comply with the overhaul's standards is impacting premium rates.
The cost of insurance co-payments for cutting-edge pharmaceuticals can vary widely from patient to patient. When the patient's share of prescription costs becomes too high, many patients skip doses or stop taking medication entirely, according to research conducted at the University of North Carolina.
On Capitol Hill, Rep. Raul Labrador says he disagreed with others in the talks about health provisions for immigrants who are here illegally now but would gain legal status under the bill. Also, CMS announces that it cannot stop sequestration cuts to Medicare's reimbursement for cancer drugs.
ProUroCare Medical Inc. announced today that on March 29, 2010 a letter was received from the FDA regarding the pending 510(k) premarket application for the Company's ProUroScan prostate imaging system. The letter indicated that the FDA could not complete its review because they believed an appropriate predicate device had not been identified.
› Verified 9 days ago